Skip to main content

Higher Administrative Payment Burden Causes Delays in Cancer Care

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

FRIDAY, Sept. 1, 2023 -- Among patients with cancer, engaging in administrative tasks to estimate costs or pay for care is associated with an increase in cost-related treatment delays or nonadherence, according to a study published online Aug. 30 in Cancer Epidemiology, Biomarkers & Prevention.

Meredith Doherty, Ph.D., from University of Pennsylvania in Philadelphia, and colleagues used data from a survey performed by the nonprofit CancerCare, which polled U.S. cancer patients and survivors about their engagement in payment-related administrative tasks and their experience with cost-associated treatment delays or nonadherence. The analysis included 510 responses.

The researchers found that when adjusting for age, race/ethnicity, education, and monthly out-of-pocket costs, participants who engaged in any administrative tasks were 18 percent more likely to experience any treatment delays or nonadherence than participants who did not engage. Each unit increase of administrative burden was associated with a 32 percent higher frequency of treatment delays or nonadherence when adjusting for age and estimated monthly out-of-pocket care costs. Age, race/ethnicity, and monthly out-of-pocket costs were more strongly associated with treatment delays or nonadherence than administrative burden. Compared with other racial and ethnic groups, African American patients were more likely to engage in administrative tasks and experience treatment delays or nonadherence. Additionally, younger patients (44 years or younger) participated in more payment-related tasks and had more cost-related delays/nonadherence than patients aged 55 years and older.

"It's fairly unique to our for-profit U.S. health care system for the consumer to be responsible for acquiring the knowledge and skills needed to effectively use those goods or services and to ensure they're of high quality," Doherty said in a statement.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Vaginal Cancer Incidence Increasing Globally

WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.